Stem cell therapy for autoimmune disease

01Overview and value chain#

Markers EC: ATMP Regulation (EC No 1394/2007) + FDA cell-therapy guidance | OECD: Bio-pharma | Regulator: FDA (USA), EMA (European Union), NMPA (China)

Stem cell therapy for autoimmune disease uses living cells — mesenchymal stromal cells (MSC) or regulatory T cells (Treg) — to re-tolerise rather than suppress the immune system, addressing lupus, Crohn’s, arthritis, GVHD and aplastic anaemia. Mesoblast’s Ryoncil (remestemcel-L) saw the FDA accept its Biologics License Application for paediatric steroid-refractory acute graft-versus-host disease; TiGenix (a Takeda company) provides Alofisel (darvadstrocel) for Crohn’s disease perianal fistulas; Cellenkos received FDA clearance for a Phase 2 trial of CK0801 (allogeneic cord-blood Treg) in aplastic anaemia; Sonoma Biotherapeutics is advancing an engineered-Treg pipeline in autoimmune disease; and GentiBio presented preclinical data for GNTI-122, an autologous antigen-specific engineered Treg.

The key directions of stem cell therapy for autoimmune disease are:

1. Mesenchymal stromal cell therapy (MSC): allogeneic MSC immunomodulation for inflammatory disease — Mesoblast (remestemcel-L/Ryoncil, steroid-refractory acute GVHD), TiGenix (darvadstrocel/Alofisel, Crohn’s perianal fistula).
2. Regulatory T-cell therapy (Treg): polyclonal or antigen-specific Treg infusion to restore tolerance — Cellenkos (CK0801 cord-blood Treg, aplastic anaemia), Sonoma Biotherapeutics (engineered Treg), GentiBio (GNTI-122 antigen-specific Treg).
3. Haematopoietic stem-cell reset (HSCT): autologous HSCT for severe refractory autoimmune disease (lupus, MS), a clinical-procedure rather than product-led approach.
4. Allogeneic off-the-shelf manufacturing (Allogeneic Manufacturing): donor-derived MSC and Treg banking that supports repeat-dose, inventory-managed cell therapy.

Sectoral value chain#

[donor MSC / cord-blood Treg / patient Treg] ──> [ex vivo activation, engineering & expansion] ──> [cryopreserved cell product]
                                              │
                                     (conditioning as needed)
                                              │
                                              ▼
[immune tolerance restored] <─── [cell infusion + immune monitoring] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• MSC immunomodulation (MSC): allogeneic MSC suppress inflammation via IDO, PGE2 and T-cell modulation, enabling off-the-shelf use across HLA barriers (Mesoblast, TiGenix).
• Treg stability and specificity (Treg): maintaining FOXP3 expression and engineering antigen-specific TCRs so the infused Treg homes to the diseased tissue (Cellenkos, Sonoma, GentiBio).
• Allogeneic off-the-shelf banking (Allogeneic Manufacturing): donor-derived MSC/Treg banked as inventory distinguishes this class from autologous cell therapy.

02US#

The US hosts Mesoblast (the MSC commercial leader), Cellenkos, Sonoma Biotherapeutics and GentiBio, and the FDA has accepted the lead MSC asset’s BLA.

Mesoblast, Cellenkos, Sonoma, GentiBio, FDA#

• Mesoblast: the FDA accepted its Biologics License Application for Ryoncil (remestemcel-L) in children with steroid-refractory acute graft-versus-host disease, the lead allogeneic-MSC regulatory asset; remestemcel-L is the most-studied MSC in inflammatory disease.
• Cellenkos: received FDA clearance to initiate a Phase 2 clinical trial of CK0801, an allogeneic cord-blood-derived Treg, for aplastic anaemia, extending Treg therapy beyond oncology into autoimmune haematology.
• Sonoma Biotherapeutics: a clinical-stage biotechnology company advancing an engineered-Treg pipeline for autoimmune disease, presenting data at the 2025 ACR meeting.
• GentiBio: presented preclinical data for GNTI-122, its autologous antigen-specific engineered Treg lead, an approach designed to restore tolerance with tissue-restricted specificity.
• FDA framework: MSC and Treg products are reviewed as advanced therapy biologics with cell-therapy-specific CMC, potency (often IDO for MSC) and long-term follow-up expectations.

03CN#

China runs an active academic-MSC autoimmune programme, with MSC clinical use in lupus and other autoimmune diseases, though it is more research- than product-led.

academic MSC, lupus, NMPA#

• Academic MSC in lupus: Chinese centres have published extensively on MSC immunosuppression in systemic lupus erythematosus (e.g. effects on dendritic cells), but enrichment returned academic literature rather than a source-confirmed commercial MSC/Treg product, so the CN block is treated qualitatively.
• NMPA framework: cell-therapy products are reviewed under the NMPA biologics framework; several MSC products are in domestic clinical use, but a dominant branded autoimmune MSC/Treg has not emerged.
• Autoimmune burden: China’s large systemic-autoimmune disease burden underpins sustained clinical interest in MSC and Treg tolerance therapy.

04EU#

Europe contributed the EU-approved MSC product Alofisel (TiGenix/Takeda) and the EMA’s central ATMP authorisation route.

TiGenix, Takeda, EMA, ATMP#

• TiGenix (Spain, a Takeda company): its Alofisel (darvadstrocel) is an EU-approved allogeneic MSC for complex perianal fistulas in adult Crohn’s disease, and Takeda provides periodic updates on the programme as the EU’s lead commercial autoimmune-MSC asset.
• EMA framework: stem-cell products are advanced therapy medicinal products centrally authorised by the European Medicines Agency under Regulation (EC) No 1394/2007, with the hospital-exemption carve-out used cautiously for autologous products.
• European CDMO: European cell-therapy CDMOs support GMP MSC expansion and cryopreservation, underpinning the allogeneic-bank model.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack pairs MSC or Treg cell sourcing with ex vivo expansion (and Treg engineering), allogeneic GMP banking, and immune-tolerance monitoring.

1. Mesenchymal stromal cell therapy (MSC):
   • Mesoblast’s Ryoncil (remestemcel-L) had its BLA accepted for paediatric steroid-refractory acute GVHD, and TiGenix’s Alofisel (darvadstrocel) is EU-approved for Crohn’s perianal fistula — the two lead commercial autoimmune/inflammatory MSC assets.
   • Allogeneic MSC act via IDO/PGE2 immunomodulation across HLA barriers, enabling off-the-shelf use.
2. Regulatory T-cell therapy (Treg):
   • Cellenkos’s CK0801 (allogeneic cord-blood Treg) entered Phase 2 in aplastic anaemia; Sonoma Biotherapeutics is clinical-stage in engineered Treg for autoimmune disease, and GentiBio presented preclinical data for GNTI-122, an antigen-specific engineered Treg.
   • Maintaining FOXP3 stability and engineering tissue-specific TCRs is what converts polyclonal Treg into disease-targeted tolerance therapy.
3. Allogeneic manufacturing (Allogeneic Manufacturing):
   • Donor-derived MSC and cord-blood Treg are banked as inventory, a structural shift from autologous cell therapy toward repeat-dose off-the-shelf cell drugs.

07Value chains and production pipelines#

Industrial pipeline of an autoimmune MSC/Treg product (ATMP Regulation)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Cell source & donor    │ ───> │ 2. Engineering &          │
└───────────────────────────┘      │    expansion             │
                                   └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Patient conditioning   │ <─── │ 3. GMP manufacture &      │
│                           │      │    banking                │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Infusion & monitoring  │ ───> │ 6. Follow-up & PV         │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Cell source and donor

Starting cells are sourced — donor bone-marrow/umbilical-cord MSC (Mesoblast, TiGenix), cord-blood Treg (Cellenkos), or autologous patient Treg (GentiBio) — with donor screening and HLA matching considered per product.

Stage 2: Engineering and expansion

MSC are expanded to therapeutic dose in culture; Treg are activated and expanded, and where antigen-specific, engineered with a tissue-homing TCR or CAR (Sonoma, GentiBio) before release testing.

Stage 3: GMP manufacture and banking

Allogeneic MSC and Treg are fill-finished, cryopreserved and banked as inventory under GMP, supporting off-the-shelf repeat-dose use; potency assays (e.g. IDO for MSC, FOXP3 for Treg) are the central release challenge.

Stage 4: Patient conditioning

MSC require minimal conditioning; some Treg protocols use low-dose lymphodepletion or IL-2 support to favour in-vivo Treg expansion and persistence.

Stage 5: Infusion and monitoring

The cell product is infused and the patient is monitored for tolerance induction (disease response, biomarker shifts) and acute infusion reactions.

Stage 6: Follow-up and pharmacovigilance

Long-term follow-up tracks durability of tolerance, need for repeat dosing, and safety (including any loss of tolerance or ectopic tissue effects), feeding the pharmacovigilance record for this still-young autoimmune cell-therapy class.